Companies › Zymeworks BC
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ZW191 | – | Phase 1 | Advanced Solid Tumors | Dec 2026 |
| ZW251 anti-GPC3 antibody-drug conjugate | GPC3 | Phase 1 | Hepatocellular Carcinoma | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06555744 | ZW191 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT07164313 | ZW251 | Phase 1 | Hepatocellular Carcinoma | Oncology | Sep 2027 |
Cash of $100m on 2026-09-30; operating cash outflow about $136m a year; runway about 9 months at that burn, to Jun 2027
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.